Boostrix-IPV replaces Repevax
The recommended vaccine offered to pregnant women (28 to 38 weeks) to protect their newborns from pertussis is changing from Repevax to Boostrix-IPV (containing diphtheria, tetanus, acellular pertussis and inactivated poliovirus).
Repevax remains available to order for the pre-school booster programme, alongside Infanrix-IPV.
Infanrix-IPV+Hib alternative to Pediacel
Additionally, Infanrix-IPV+Hib has been introduced as an alternative infant vaccine for the primary immunisation programme, alongside Pediacel. The two vaccines are interchangeable; however, where possible the same brand should be used for all 3 doses of the primary vaccine course.
Both vaccines protect against diphtheria, tetanus, whooping cough, polio and Hib. Infanrix-IPV+Hib contains 3 pertussis components, whilst Pediacel has 5 components but with a slightly lower antigen content. Post-licensing surveillance has not shown any differences between the vaccines in effectiveness or disease control. Pediacel is supplied as a pre-filled syringe whereas Infanrix-IPV+Hib requires reconstitution before administration.
Further information: GlaxoSmithKline